Levothyroxine Capsules vs. Tablets: Absorption Comparison
Levothyroxine capsules (liquid-filled soft gel formulations) demonstrate superior absorption compared to tablets, particularly in patients with conditions that impair gastric acid secretion or those taking medications that interfere with absorption. 1
Key Evidence on Absorption Differences
In Vitro Dissolution Studies
The liquid capsule preparation (Tirosint®) shows dissolution profiles that are least affected by changes in pH compared to tablet formulations 1. This is clinically significant because tablet dissolution is highly pH-dependent, making tablets more vulnerable to absorption issues in patients with:
- Diminished gastric acid secretion
- Atrophic gastritis
- Proton pump inhibitor (PPI) or H2 blocker use
Clinical Studies in Special Populations
Patients on PPIs or with gastric disorders:
- In thyroidectomized patients taking PPIs, switching from tablets to soft gel capsules at the same dose resulted in:
- Significant TSH decrease (mean -0.68 mIU/L at 12 weeks)
- Increased thyroid hormone levels (fT3 and TT3)
- Improved lipid profiles and CPK levels 2
Head-to-head comparison study: A study comparing all three formulations (tablets, liquid, soft gel capsules) in the same patients found 3:
- Without interfering medications: TSH levels were 2.38 ± 0.69 mU/L (tablets) vs. 1.77 ± 0.44 mU/L (capsules) vs. 1.62 ± 0.51 mU/L (liquid)
- With interfering medications: TSH levels were 7.53 ± 2.82 mU/L (tablets) vs. 2.70 ± 0.79 mU/L (capsules) vs. 2.74 ± 0.98 mU/L (liquid)
- Rates of achieving TSH ≤2.50 mU/L: 64.4% (tablets) vs. 95.9% (capsules) vs. 97.4% (liquid) without interfering drugs
Pharmacokinetic Advantages
Faster onset of absorption: Liquid formulations show approximately 30 minutes faster time to maximum concentration compared to tablets, with greater early exposure (AUC 0-2h) 4. This faster absorption may help minimize drug-food interactions.
Clinical Implications and Guideline Recommendations
When to Consider Capsule Formulations
Strong indications for capsules over tablets:
- Patients taking PPIs or H2 receptor blockers chronically
- Atrophic gastritis or other conditions causing hypochlorhydria
- Malabsorption syndromes
- Post-bariatric surgery patients
- Gastroparesis 5
- Patients with persistent TSH elevation despite appropriate tablet doses
Important Caveats
Dose adjustment required when switching: When converting from tablets to capsules, patients often require dose reduction to maintain euthyroidism 3. The improved bioavailability means the same nominal dose delivers more active hormone. Monitor TSH 6-8 weeks after switching formulations 1.
Consistency is key: Regardless of formulation chosen, guidelines emphasize using a consistent levothyroxine preparation for individual patients to minimize variability 1. The improved absorption of capsules doesn't eliminate the need for proper administration technique (fasting, avoiding interfering substances).
Cost and Practical Considerations
While capsules offer absorption advantages, they are typically more expensive than generic tablets. For patients without absorption issues who achieve euthyroidism on tablets with proper administration technique, switching may not be necessary. However, for the substantial proportion of patients with malabsorption or drug interactions, capsules represent a clinically superior option that may reduce the need for dose escalation and improve thyroid control 6, 7.
The clinical significance of better absorption translates to improved TSH control, potentially better symptom management, and reduced risk of both under-treatment and over-treatment complications.